Format

Send to

Choose Destination
Clin Pharmacol Ther. 2010 May;87(5):558-62. doi: 10.1038/clpt.2009.232. Epub 2010 Feb 3.

ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin.

Author information

1
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong. btomlinson@cuhk.edu.hk

Abstract

The ATP-binding cassette G2 (ABCG2) c.421C>A (rs2231142) polymorphism influences the pharmacokinetics of rosuvastatin. We examined whether this polymorphism influences the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy of the drug. In 305 Chinese patients with hypercholesterolemia who were treated with rosuvastatin at a dosage of 10 mg daily, the c.421A variant was found to be significantly associated with greater reduction in LDL-C level, in a gene-dose-dependent manner. As compared with subjects with the c.421CC genotype, those with the c.421AA genotype showed a 6.9% greater reduction in LDL-C level, which would be equivalent to the effect obtained by doubling the dose of rosuvastatin.

PMID:
20130569
DOI:
10.1038/clpt.2009.232
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center